158 related articles for article (PubMed ID: 22990204)
1. OSU-03012 interacts with lapatinib to kill brain cancer cells.
Booth L; Cruickshanks N; Ridder T; Chen CS; Grant S; Dent P
Cancer Biol Ther; 2012 Dec; 13(14):1501-11. PubMed ID: 22990204
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.
Hamed HA; Tavallai S; Grant S; Poklepovic A; Dent P
J Cell Physiol; 2015 Jan; 230(1):131-9. PubMed ID: 24911215
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
Mitchell C; Yacoub A; Hossein H; Martin AP; Bareford MD; Eulitt P; Yang C; Nephew KP; Dent P
Cancer Biol Ther; 2010 Nov; 10(9):903-17. PubMed ID: 20855960
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation.
Martin AP; Miller A; Emad L; Rahmani M; Walker T; Mitchell C; Hagan MP; Park MA; Yacoub A; Fisher PB; Grant S; Dent P
Mol Pharmacol; 2008 Sep; 74(3):807-22. PubMed ID: 18544666
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.
Cruickshanks N; Hamed HA; Bareford MD; Poklepovic A; Fisher PB; Grant S; Dent P
Mol Pharmacol; 2012 May; 81(5):748-58. PubMed ID: 22357666
[TBL] [Abstract][Full Text] [Related]
6. OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing.
Booth L; Cazanave SC; Hamed HA; Yacoub A; Ogretmen B; Chen CS; Grant S; Dent P
Cancer Biol Ther; 2012 Feb; 13(4):224-36. PubMed ID: 22354011
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
Cruickshanks N; Hamed HA; Booth L; Tavallai S; Syed J; Sajithlal GB; Grant S; Poklepovic A; Dent P
Cancer Biol Ther; 2013 Oct; 14(10):982-96. PubMed ID: 24025251
[TBL] [Abstract][Full Text] [Related]
8. Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.
Park MA; Zhang G; Mitchell C; Rahmani M; Hamed H; Hagan MP; Yacoub A; Curiel DT; Fisher PB; Grant S; Dent P
Mol Cancer Ther; 2008 Sep; 7(9):2633-48. PubMed ID: 18790746
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.
Martin AP; Mitchell C; Rahmani M; Nephew KP; Grant S; Dent P
Cancer Biol Ther; 2009 Nov; 8(21):2084-96. PubMed ID: 19823038
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
Xia W; Husain I; Liu L; Bacus S; Saini S; Spohn J; Pry K; Westlund R; Stein SH; Spector NL
Cancer Res; 2007 Feb; 67(3):1170-5. PubMed ID: 17283152
[TBL] [Abstract][Full Text] [Related]
11. 17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species.
Walker T; Mitchell C; Park MA; Yacoub A; Rahmani M; Häussinger D; Reinehr R; Voelkel-Johnson C; Fisher PB; Grant S; Dent P
Mol Cancer Ther; 2010 May; 9(5):1378-95. PubMed ID: 20442308
[TBL] [Abstract][Full Text] [Related]
12. Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors.
Wang YC; Kulp SK; Wang D; Yang CC; Sargeant AM; Hung JH; Kashida Y; Yamaguchi M; Chang GD; Chen CS
Cancer Res; 2008 Apr; 68(8):2820-30. PubMed ID: 18413750
[TBL] [Abstract][Full Text] [Related]
13. OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells.
Park MA; Yacoub A; Rahmani M; Zhang G; Hart L; Hagan MP; Calderwood SK; Sherman MY; Koumenis C; Spiegel S; Chen CS; Graf M; Curiel DT; Fisher PB; Grant S; Dent P
Mol Pharmacol; 2008 Apr; 73(4):1168-84. PubMed ID: 18182481
[TBL] [Abstract][Full Text] [Related]
14. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells.
Yacoub A; Park MA; Hanna D; Hong Y; Mitchell C; Pandya AP; Harada H; Powis G; Chen CS; Koumenis C; Grant S; Dent P
Mol Pharmacol; 2006 Aug; 70(2):589-603. PubMed ID: 16622074
[TBL] [Abstract][Full Text] [Related]
15. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
[TBL] [Abstract][Full Text] [Related]
16. OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2.
West NW; Garcia-Vargas A; Chalfant CE; Park MA
BMC Cancer; 2013 May; 13():256. PubMed ID: 23706161
[TBL] [Abstract][Full Text] [Related]
17. OSU-03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood-Brain Barrier: Implications for Anti-Cancer Therapies.
Booth L; Roberts JL; Tavallai M; Nourbakhsh A; Chuckalovcak J; Carter J; Poklepovic A; Dent P
J Cell Physiol; 2015 Aug; 230(8):1982-98. PubMed ID: 25736380
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib and HDAC inhibitors interact to kill sarcoma cells.
Tavallai S; Hamed HA; Grant S; Poklepovic A; Dent P
Cancer Biol Ther; 2014 May; 15(5):578-85. PubMed ID: 24556916
[TBL] [Abstract][Full Text] [Related]
19. Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.
Singla S; Pippin JA; Drebin JA
Oncol Rep; 2012 Dec; 28(6):2211-6. PubMed ID: 23007710
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
Leow CC; Chesebrough J; Coffman KT; Fazenbaker CA; Gooya J; Weng D; Coats S; Jackson D; Jallal B; Chang Y
Mol Cancer Ther; 2009 Aug; 8(8):2131-41. PubMed ID: 19671750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
